Melatonin
Synopsis
Kanser, her yıl yaklaşık 10 milyon insanın ölümüne neden olan geniş bir hastalık grubunu temsil etmektedir. Kanseri tedavi etmek için cerrahi rezeksiyon, immünoterapi, kemoterapi ve radyoterapi dahil olmak üzere çeşitli tedavi stratejileri kullanılır. Endojen bir hormon olan melatonin sirkadiyen ritmin düzenlenmesiyle ilişkilidir. Melatoninin uyku-uyanıklık döngüsü kontrolünün yanı sıra son yıllarda antikanser etkilerini açıklayan birçok çalışma bulunmaktadır. Bu durum melatoninin klinikte kanser tedavisi için kullanılabileceğini düşündürsede, geniş klinik uygulama için kabul edilmesinin önünde hala büyük engeller bulunmaktadır. Antikanser etkilerinin ardındaki kesin mekanizmalar belirsizliğini koruyor ve melatoninin spesifik özellikleri onun in vivo çalışmalarını engelliyor. Bu bölümde melatonin çalışmalarındaki son gelişmeleri özetleyeceğiz. Son olarak melatoninin kanser tedavisinde kullanımının önündeki engelleri açıklamaya çalışacağız.
Cancer represents a large group of diseases that cause the death of approximately 10 million people each year. Various treatment strategies are used to treat cancer, including surgical resection, immunotherapy, chemotherapy and radiotherapy. Melatonin, an endogenous hormone, is associated with the regulation of circadian rhythm. In addition to melatonin's sleep-wake cycle control, there are many studies in recent years explaining its anticancer effects. Although this suggests that melatonin can be used in the clinic for cancer treatment, there are still major obstacles to its acceptance for wide clinical application. The exact mechanisms behind its anticancer effects remain unclear, and the specific properties of melatonin hinder its in vivo studies. In this section we will summarize the latest advances in melatonin studies. Finally, we will try to explain the obstacles to the use of melatonin in cancer treatment.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. A Cancer Journal of Clinicians. 2021;71(3): 209–249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
Wang P, Ren FM, Lin Y, et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Medicine. 2015;16(4), 462–468. doi: 10.1016/j.sleep.2014.11.017. Epub 2015 Feb 3.
Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Supportive Care in Cancer. 2016;24(3), 1097–1105. doi: 10.1007/s00520-015-2883-6. Epub 2015 Aug 11.
Lozano A, Marruecos J, Rubió J, et al. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clinical and Translational Oncology. 2021;23(9), 1801–1810. doi: 10.1007/s12094-021-02586-w
Elsabagh HH, Moussa E, Mahmoud SA, et al. Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Diseases. 2020;26(3), 566–572. doi: https://doi.org/10.1111/odi.13265
Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro Endocrinology Letters. 2003;24(1-2), 83–85.
Persson C, Glimelius B, Rönnelid, J, et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: A randomized pilot study. Nutrition. 2005;21(2), 170–178. doi: 10.1016/j.nut.2004.05.026
Barni S, Lissoni P, Cazzaniga M, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology. 1995;52(3), 243–245. doi: 10.1159/000227465
Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer. 1995;71(4), 854–856. doi: 10.1038/bjc.1995.164
Schernhammer ES, Giobbie-Hurder A, Gantman K, et al. A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes and Control. 2012;23(4), 609–616. doi: 10.1007/s10552-012-9927-8
Sookprasert A, Johns NP, Phunmanee A, et al. Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial. Anticancer Research. 2014;34(12), 7327–7337.
Seely D, Legacy M, Auer RC, et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial. EClinicalMedicine. 2021;33, 100763. doi: 10.1016/j.eclinm.2021.100763
Lee JH, Yoon YM, Han Y-S, et al. Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. Anticancer Research. 2018;38(4), 1993–2000. doi: 10.21873/anticanres.12437
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3), 422–431. doi: 10.1093/carcin/bgy186
Liu Z, Sang X, Wang M, et al. Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. Oncogene. 2021;40(44), 6273–6283. doi: 10.1038/s41388-021-02015-w
Najafi M, Salehi E, Farhood B, et al. Adjuvant chemotherapy with melatonin for targeting human cancers: A review. Journal of Cellular Physiology. 2019;234(3), 2356–2372. doi: 10.1002/jcp.27259
Alonso-González C, González A, Menéndez-Menéndez J, et al. Melatonin as a Radio-Sensitizer in Cancer. Biomedicines. 2020;8(8), 247. doi: 10.3390/biomedicines8080247
Zhang M, Zhang M, Li R, et al. Melatonin sensitizes esophageal cancer cells to 5-fluorouracil via promotion of apoptosis by regulating EZH2 expression. Oncology Reports. 2021;45(4), 22. doi: 10.3892/or.2021.7973
Zhao Y, Wang C, Goel A. A combined treatment with melatonin and andrographis promotes autophagy and anti-cancer activity in colorectal cancer. Carcinogenesis. 2022;43(3), 217-230. doi: 10.1093/carcin/bgac008
Tran QH, Hoang DH, Song M, et al. Melatonin and doxorubicin synergistically enhance apoptosis via autophagy-dependent reduction of AMPKα1 transcription in human breast cancer cells. Experimental and Molecular Medicine. 2021;53(9), 1413–1422. doi: 10.1038/s12276-021-00675-y
González-González A, Nieto EG, González A, et al. Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts. International Journal of Molecular Sciences. 2019;20(16), 3935. doi: 10.3390/ijms20163935
Lissoni P, Meregalli S, Nosetto L, et al. Increased Survival Time in Brain Glioblastomas by a Radioneuroendocrine Strategy with Radiotherapy plus Melatonin Compared to Radiotherapy Alone. Oncology. 1996;53(1), 43–46. doi: 10.1159/000227533
Berk L, Berkey B, Rich T, et al. Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). International Journal of Radiation Oncology, Biology, Physics. 2007;68(3), 852–857. doi: 10.1016/j.ijrobp.2007.01.012
Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832), 1107–1111. doi: 10.1038/35074122
Rahimi SB, Mohebbi A, Vakilzadeh G, et al. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Archives of Virology. 2018;163(3), 587–597. doi: 10.1007/s00705-017-3647-z
Moreno ACR, Porchia BFMM, Pagni RL, et al. The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors. Frontiers in Immunology. 2018;9, 1914. doi: https://doi.org/10.3389/fimmu.2018.01914
Liu Z, Han C, Fu Y-X. Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology. 2020;17(1) 13–26. doi: 10.1038/s41423-019-0341-y
Lissoni P, Barni S, Cazzaniga M, et al. Efficacy of the Concomitant Administration of the Pineal Hormone Melatonin in Cancer Immunotherapy with Low-Dose IL-2 in Patients with Advanced Solid Tumors Who Had Progressed on IL-2 Alone. Oncology. 1994;51(4), 344–347. doi: 10.1159/000227362
Capelli E, Campo I, Panelli S, et al. Evaluation of gene expression in human lymphocytes activated in the presence of melatonin. International Immunopharmacology. 2002;2(7), 885–892. doi: 10.1016/s1567-5769(02)00021-8
Chao Y-C, Lee K-Y, Wu S-M, et al. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2021; 22(11), 5649. doi: 10.3390/ijms22115649
Lissoni P, Messina G, Borsotti G, et al. Modulation of Immune and Anti-Tumor Effects of Cancer Immunotherapy With Anti-Pd-1 Monoclonal Antibodies by the Pineal Hormone Melatonin: Preliminary Clinical Results. Journal of Immunology and Allergy. 2020;1(1), 1–6.
Harpsøe NG, Andersen LPH, Gögenur I, et al. Clinical pharmacokinetics of melatonin: A systematic review. European Journal of Clinical Pharmacology. 2015;71(8), 901–909. doi: 10.1007/s00228-015-1873-4
Pranil T, Moongngarm A, Loypimai P. Influence of pH, temperature, and light on the stability of melatonin in aqueous solutions and fruit juices. Heliyon. 2020;6(3), e03648. doi: 10.1016/j.heliyon.2020.e03648
Daya S, Walker RB, Glass BD, et al. The effect of variations in pH and temperature on stability of melatonin in aqueous solution. Journal of Pineal Research. 2001;31(2), 155–158. doi: 10.1034/j.1600-079x.2001.310209.x
Zetner D, Rosenberg J. Solubility and stability of melatonin in propylene glycol, glycofurol, and dimethyl sulfoxide. F1000Research. 2020;9, 85. doi: 10.12688/f1000research.21992.1
Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International Journal of Nanomedicine. 2017;12, 7291–7309. doi: 10.2147/IJN.S146315
Niu G, Yousefi B, Qujeq D, et al. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells. Material Science and Engineering. C, Materials for Biological Applications. 2020;119, 111554. doi: 10.1016/j.msec.2020.111554
Sabzichi M, Samadi N, Mohammadian J, et al. Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Colloids and Surfaces. B Biointerfaces. 2016;145, 64–71. Doi: 10.1016/j.colsurfb.2016.04.042
Shokrzadeh M, Ghassemi-Barghi N. Melatonin Loading Chitosan-Tripolyphosphate Nanoparticles: Application in Attenuating Etoposide-Induced Genotoxicity in HepG2 Cells. Pharmacology. 2018;102(1-2), 74–80. doi: 10.1159/000489667
Zhang W, Zhao W, Li Q, et al. 3D-printing magnesium– polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures. Journal of Nanobiotechnology. 2021;19, 263. doi: https://doi.org/10.1186/s12951-021-01012-1
Mirza-Aghazadeh-Attari M, Mihanfar A, Yousefi B, et al. Nanotechnology-based advances in the efficient delivery of melatonin. Cancer Cell International. 2022;22(1), 43. doi: 10.1186/s12935-022-02472-7
Kennaway DJ. Measuring melatonin by immunoassay. Journal of Pineal Research. 2020;69(1), e12657. Doi: 10.1111/jpi.12657
van Faassen M, Bischoff R, Kema IP. Relationship between plasma and salivary melatonin and cortisol investigated by LC-MS/MS. Clinical Chemistry and Laboratory Medicine. 2017;55(9), 1340–1348. doi: 10.1515/cclm-2016-0817
Rzepka-Migut B, Paprocka J. Melatonin-Measurement Methods and the Factors Modifying the Results. A Systematic Review of the Literature. International Journal of Environmental Research and Public Health. 2020;17(6), 1916. doi: 10.3390/ijerph17061916
Middleton B. Measurement of melatonin and 6-sulphatoxymelatonin. Methods in Molecular Biology. 2013;1065, 171–199. doi: 10.1007/978-1-62703-616-0_11
Kennaway DJ. A critical review of melatonin assays: Past and present. Journal of Pineal Research. 2019;67(1), e12572. doi: 10.1111/jpi.12572
Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complementary Therapies in Medicine. 2018;42, 65–81. doi: 10.1016/j.ctim.2018.11.003
Zhang J, Jiang H, Du K, et al. Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. Journal of Pineal Research. 2021;71(3), e12758. doi: 10.1111/jpi.12758
Jafarpour SM, Shekarchi B, Bagheri H, et al. The radioprotective effects of melatonin and nanoselenium on DNA double-strand breaks in peripheral lymphocytes caused by I-131. Indian Journal of Nuclear Medicine. 2021;36(2), 134–139. doi: 10.4103/ijnm.IJNM_179_20
Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24), 39896–39921. doi: 10.18632/oncotarget.16379
Zhang N, Sundquist J, Sundquist K, et al. Use of Melatonin Is Associated With Lower Risk of Colorectal Cancer in Older Adults. Clinical and Translational Gastroenterology. 2021;12(8), e00396. doi: 10.14309/ctg.0000000000000396
Wong ATY, Fensom GK, Key TJ, et al. Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case–Control Analysis in the DOM Study and Meta-analysis of Prospective Studies. Cancer Epidemiology, Biomarkers and Prevention. 2021;30(1), 97–103. doi: 10.1158/1055-9965.EPI-20-0822
Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda, et al. Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. International Journal of Molecular Sciences. 2020;21(2), 548. doi: 10.3390/ijms21020548
Li W, Kwok CC-H, Chan DC-W, et al. Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: Prospective cohort study. Sleep Medicine. 2019;55, 14–21. doi: 10.1016/j.sleep.2018.11.022
Novik AV, Protsenko SA, Baldueva IA, et al. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma. The Oncologist. 2021;26(5), 364–e734. doi: 10.1002/onco.13761
Härtter S, Ursing C, Morita S, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study. Clinical Pharmacology and Therapeutics. 2001;70(1), 10–16. doi: 10.1067/mcp.2001.116512
Wang P, Ren FM, Lin Y, et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Medicine. 2015;16(4), 462–468. doi: 10.1016/j.sleep.2014.11.017. Epub 2015 Feb 3.
Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Supportive Care in Cancer. 2016;24(3), 1097–1105. doi: 10.1007/s00520-015-2883-6. Epub 2015 Aug 11.
Lozano A, Marruecos J, Rubió J, et al. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clinical and Translational Oncology. 2021;23(9), 1801–1810. doi: 10.1007/s12094-021-02586-w
Elsabagh HH, Moussa E, Mahmoud SA, et al. Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Diseases. 2020;26(3), 566–572. doi: https://doi.org/10.1111/odi.13265
Lissoni P, Malugani F, Bukovec R, et al. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Neuro Endocrinology Letters. 2003;24(1-2), 83–85.
Persson C, Glimelius B, Rönnelid, J, et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: A randomized pilot study. Nutrition. 2005;21(2), 170–178. doi: 10.1016/j.nut.2004.05.026
Barni S, Lissoni P, Cazzaniga M, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology. 1995;52(3), 243–245. doi: 10.1159/000227465
Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer. 1995;71(4), 854–856. doi: 10.1038/bjc.1995.164
Schernhammer ES, Giobbie-Hurder A, Gantman K, et al. A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes and Control. 2012;23(4), 609–616. doi: 10.1007/s10552-012-9927-8
Sookprasert A, Johns NP, Phunmanee A, et al. Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial. Anticancer Research. 2014;34(12), 7327–7337.
Seely D, Legacy M, Auer RC, et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe): A randomized placebo controlled clinical trial. EClinicalMedicine. 2021;33, 100763. doi: 10.1016/j.eclinm.2021.100763
Lee JH, Yoon YM, Han Y-S, et al. Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. Anticancer Research. 2018;38(4), 1993–2000. doi: 10.21873/anticanres.12437
Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3), 422–431. doi: 10.1093/carcin/bgy186
Liu Z, Sang X, Wang M, et al. Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. Oncogene. 2021;40(44), 6273–6283. doi: 10.1038/s41388-021-02015-w
Najafi M, Salehi E, Farhood B, et al. Adjuvant chemotherapy with melatonin for targeting human cancers: A review. Journal of Cellular Physiology. 2019;234(3), 2356–2372. doi: 10.1002/jcp.27259
Alonso-González C, González A, Menéndez-Menéndez J, et al. Melatonin as a Radio-Sensitizer in Cancer. Biomedicines. 2020;8(8), 247. doi: 10.3390/biomedicines8080247
Zhang M, Zhang M, Li R, et al. Melatonin sensitizes esophageal cancer cells to 5-fluorouracil via promotion of apoptosis by regulating EZH2 expression. Oncology Reports. 2021;45(4), 22. doi: 10.3892/or.2021.7973
Zhao Y, Wang C, Goel A. A combined treatment with melatonin and andrographis promotes autophagy and anti-cancer activity in colorectal cancer. Carcinogenesis. 2022;43(3), 217-230. doi: 10.1093/carcin/bgac008
Tran QH, Hoang DH, Song M, et al. Melatonin and doxorubicin synergistically enhance apoptosis via autophagy-dependent reduction of AMPKα1 transcription in human breast cancer cells. Experimental and Molecular Medicine. 2021;53(9), 1413–1422. doi: 10.1038/s12276-021-00675-y
González-González A, Nieto EG, González A, et al. Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts. International Journal of Molecular Sciences. 2019;20(16), 3935. doi: 10.3390/ijms20163935
Lissoni P, Meregalli S, Nosetto L, et al. Increased Survival Time in Brain Glioblastomas by a Radioneuroendocrine Strategy with Radiotherapy plus Melatonin Compared to Radiotherapy Alone. Oncology. 1996;53(1), 43–46. doi: 10.1159/000227533
Berk L, Berkey B, Rich T, et al. Randomized Phase II Trial of High-Dose Melatonin and Radiation Therapy for RPA Class 2 Patients With Brain Metastases (RTOG 0119). International Journal of Radiation Oncology, Biology, Physics. 2007;68(3), 852–857. doi: 10.1016/j.ijrobp.2007.01.012
Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832), 1107–1111. doi: 10.1038/35074122
Rahimi SB, Mohebbi A, Vakilzadeh G, et al. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Archives of Virology. 2018;163(3), 587–597. doi: 10.1007/s00705-017-3647-z
Moreno ACR, Porchia BFMM, Pagni RL, et al. The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors. Frontiers in Immunology. 2018;9, 1914. doi: https://doi.org/10.3389/fimmu.2018.01914
Liu Z, Han C, Fu Y-X. Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology. 2020;17(1) 13–26. doi: 10.1038/s41423-019-0341-y
Lissoni P, Barni S, Cazzaniga M, et al. Efficacy of the Concomitant Administration of the Pineal Hormone Melatonin in Cancer Immunotherapy with Low-Dose IL-2 in Patients with Advanced Solid Tumors Who Had Progressed on IL-2 Alone. Oncology. 1994;51(4), 344–347. doi: 10.1159/000227362
Capelli E, Campo I, Panelli S, et al. Evaluation of gene expression in human lymphocytes activated in the presence of melatonin. International Immunopharmacology. 2002;2(7), 885–892. doi: 10.1016/s1567-5769(02)00021-8
Chao Y-C, Lee K-Y, Wu S-M, et al. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2021; 22(11), 5649. doi: 10.3390/ijms22115649
Lissoni P, Messina G, Borsotti G, et al. Modulation of Immune and Anti-Tumor Effects of Cancer Immunotherapy With Anti-Pd-1 Monoclonal Antibodies by the Pineal Hormone Melatonin: Preliminary Clinical Results. Journal of Immunology and Allergy. 2020;1(1), 1–6.
Harpsøe NG, Andersen LPH, Gögenur I, et al. Clinical pharmacokinetics of melatonin: A systematic review. European Journal of Clinical Pharmacology. 2015;71(8), 901–909. doi: 10.1007/s00228-015-1873-4
Pranil T, Moongngarm A, Loypimai P. Influence of pH, temperature, and light on the stability of melatonin in aqueous solutions and fruit juices. Heliyon. 2020;6(3), e03648. doi: 10.1016/j.heliyon.2020.e03648
Daya S, Walker RB, Glass BD, et al. The effect of variations in pH and temperature on stability of melatonin in aqueous solution. Journal of Pineal Research. 2001;31(2), 155–158. doi: 10.1034/j.1600-079x.2001.310209.x
Zetner D, Rosenberg J. Solubility and stability of melatonin in propylene glycol, glycofurol, and dimethyl sulfoxide. F1000Research. 2020;9, 85. doi: 10.12688/f1000research.21992.1
Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International Journal of Nanomedicine. 2017;12, 7291–7309. doi: 10.2147/IJN.S146315
Niu G, Yousefi B, Qujeq D, et al. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells. Material Science and Engineering. C, Materials for Biological Applications. 2020;119, 111554. doi: 10.1016/j.msec.2020.111554
Sabzichi M, Samadi N, Mohammadian J, et al. Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Colloids and Surfaces. B Biointerfaces. 2016;145, 64–71. Doi: 10.1016/j.colsurfb.2016.04.042
Shokrzadeh M, Ghassemi-Barghi N. Melatonin Loading Chitosan-Tripolyphosphate Nanoparticles: Application in Attenuating Etoposide-Induced Genotoxicity in HepG2 Cells. Pharmacology. 2018;102(1-2), 74–80. doi: 10.1159/000489667
Zhang W, Zhao W, Li Q, et al. 3D-printing magnesium– polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures. Journal of Nanobiotechnology. 2021;19, 263. doi: https://doi.org/10.1186/s12951-021-01012-1
Mirza-Aghazadeh-Attari M, Mihanfar A, Yousefi B, et al. Nanotechnology-based advances in the efficient delivery of melatonin. Cancer Cell International. 2022;22(1), 43. doi: 10.1186/s12935-022-02472-7
Kennaway DJ. Measuring melatonin by immunoassay. Journal of Pineal Research. 2020;69(1), e12657. Doi: 10.1111/jpi.12657
van Faassen M, Bischoff R, Kema IP. Relationship between plasma and salivary melatonin and cortisol investigated by LC-MS/MS. Clinical Chemistry and Laboratory Medicine. 2017;55(9), 1340–1348. doi: 10.1515/cclm-2016-0817
Rzepka-Migut B, Paprocka J. Melatonin-Measurement Methods and the Factors Modifying the Results. A Systematic Review of the Literature. International Journal of Environmental Research and Public Health. 2020;17(6), 1916. doi: 10.3390/ijerph17061916
Middleton B. Measurement of melatonin and 6-sulphatoxymelatonin. Methods in Molecular Biology. 2013;1065, 171–199. doi: 10.1007/978-1-62703-616-0_11
Kennaway DJ. A critical review of melatonin assays: Past and present. Journal of Pineal Research. 2019;67(1), e12572. doi: 10.1111/jpi.12572
Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complementary Therapies in Medicine. 2018;42, 65–81. doi: 10.1016/j.ctim.2018.11.003
Zhang J, Jiang H, Du K, et al. Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. Journal of Pineal Research. 2021;71(3), e12758. doi: 10.1111/jpi.12758
Jafarpour SM, Shekarchi B, Bagheri H, et al. The radioprotective effects of melatonin and nanoselenium on DNA double-strand breaks in peripheral lymphocytes caused by I-131. Indian Journal of Nuclear Medicine. 2021;36(2), 134–139. doi: 10.4103/ijnm.IJNM_179_20
Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24), 39896–39921. doi: 10.18632/oncotarget.16379
Zhang N, Sundquist J, Sundquist K, et al. Use of Melatonin Is Associated With Lower Risk of Colorectal Cancer in Older Adults. Clinical and Translational Gastroenterology. 2021;12(8), e00396. doi: 10.14309/ctg.0000000000000396
Wong ATY, Fensom GK, Key TJ, et al. Urinary Melatonin in Relation to Breast Cancer Risk: Nested Case–Control Analysis in the DOM Study and Meta-analysis of Prospective Studies. Cancer Epidemiology, Biomarkers and Prevention. 2021;30(1), 97–103. doi: 10.1158/1055-9965.EPI-20-0822
Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda, et al. Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. International Journal of Molecular Sciences. 2020;21(2), 548. doi: 10.3390/ijms21020548
Li W, Kwok CC-H, Chan DC-W, et al. Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: Prospective cohort study. Sleep Medicine. 2019;55, 14–21. doi: 10.1016/j.sleep.2018.11.022
Novik AV, Protsenko SA, Baldueva IA, et al. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma. The Oncologist. 2021;26(5), 364–e734. doi: 10.1002/onco.13761
Härtter S, Ursing C, Morita S, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study. Clinical Pharmacology and Therapeutics. 2001;70(1), 10–16. doi: 10.1067/mcp.2001.116512
Pages
293-302
Published
March 11, 2024
Copyright (c) 2024 Academician Publishing Book Portal
License
LicenseHow to Cite
1.
Turhan A. Melatonin. In: Sakin A, editor. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim [Internet]. Türkiye: Academician Publishing Book DOI Portal; 2024 [cited 2026 Jul. 13]. pp. 293-302. Available from: https://www.omp35.books.akademisyen.net/index.php/akya/catalog/book/2380/chapter/13931
